Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor ; day:15 ; month:7 ; year:2023 ; pages:1-2
European journal of nuclear medicine and molecular imaging ; (15.7.2023), 1-2
- Urheber
-
Opalinska, Marta
Lezaic, Luka
Decristoforo, Clemens
Kolenc, Petra
Mikolajczak, Renata
Studen, Andrej
Simoncic, Urban
Virgolini, Irene
Trofimiuk-Muldner, Malgorzata
Garnuszek, Piotr
Rangger, Christine
Fani, Melpomeni
Glowa, Boguslaw
Skorkiewicz, Konrad
Hubalewska-Dydejczyk, Alicja
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-023-06335-9
- URN
-
urn:nbn:de:101:1-2023102408393895028370
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Opalinska, Marta
- Lezaic, Luka
- Decristoforo, Clemens
- Kolenc, Petra
- Mikolajczak, Renata
- Studen, Andrej
- Simoncic, Urban
- Virgolini, Irene
- Trofimiuk-Muldner, Malgorzata
- Garnuszek, Piotr
- Rangger, Christine
- Fani, Melpomeni
- Glowa, Boguslaw
- Skorkiewicz, Konrad
- Hubalewska-Dydejczyk, Alicja
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy](/assets/placeholder/searchResultMediaUnknown.png)
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT
The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
Non-functional urinary bladder paraganglioma with negative Ga-DOTA-NOC PET/CT uptake
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT
The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
Non-functional urinary bladder paraganglioma with negative Ga-DOTA-NOC PET/CT uptake
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT
The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
Non-functional urinary bladder paraganglioma with negative Ga-DOTA-NOC PET/CT uptake
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model